Eliana Merle
Stock Analyst at Barclays
(3.67)
# 751
Out of 5,165 analysts
107
Total ratings
49.4%
Success rate
7.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Initiates: Overweight | $923 | $756.91 | +21.94% | 1 | Mar 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $80 → $105 | $57.43 | +82.83% | 4 | Mar 4, 2026 | |
| TPG TPG Inc. | Maintains: Overweight | $69 → $56 | $39.50 | +41.77% | 2 | Mar 2, 2026 | |
| GOSS Gossamer Bio | Downgrades: Underweight | $9 → $0.3 | $0.46 | -34.21% | 5 | Feb 24, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $606 → $607 | $466.10 | +30.23% | 2 | Feb 17, 2026 | |
| QURE uniQure | Initiates: Equal-Weight | $31 | $15.94 | +94.48% | 5 | Jan 28, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | $59 | $37.01 | +59.42% | 2 | Jan 28, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Equal-Weight | $8 | $5.14 | +55.64% | 2 | Jan 28, 2026 | |
| PTCT PTC Therapeutics | Upgrades: Overweight | $68 → $119 | $66.75 | +78.28% | 1 | Jan 28, 2026 | |
| MBX MBX Biosciences | Initiates: Overweight | $66 | $29.80 | +121.48% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $964 | $440.83 | +118.68% | 6 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.08 | +196.05% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $231 | $144.60 | +59.75% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $342 | $231.03 | +48.04% | 3 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $8.48 | +289.15% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $71.03 | +12.63% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $24 | $18.87 | +27.19% | 9 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $318.91 | +65.25% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $40 → $34 | $53.31 | -36.22% | 9 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $3.62 | +562.98% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $64.78 | -69.13% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $16.66 | -27.97% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.15 | +272.09% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $12.28 | +71.01% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $79.60 | -12.06% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $2.71 | -18.82% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $99.00 | -28.28% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $90.54 | +44.69% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $23.31 | -78.55% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $46.07 | -60.93% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $16.35 | +34.56% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $8.79 | +434.70% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.37 | +11.34% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $32.70 | +309.79% | 3 | Aug 19, 2020 |
Regeneron Pharmaceuticals
Mar 6, 2026
Initiates: Overweight
Price Target: $923
Current: $756.91
Upside: +21.94%
BioMarin Pharmaceutical
Mar 4, 2026
Maintains: Overweight
Price Target: $80 → $105
Current: $57.43
Upside: +82.83%
TPG Inc.
Mar 2, 2026
Maintains: Overweight
Price Target: $69 → $56
Current: $39.50
Upside: +41.77%
Gossamer Bio
Feb 24, 2026
Downgrades: Underweight
Price Target: $9 → $0.3
Current: $0.46
Upside: -34.21%
Vertex Pharmaceuticals
Feb 17, 2026
Maintains: Overweight
Price Target: $606 → $607
Current: $466.10
Upside: +30.23%
uniQure
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $31
Current: $15.94
Upside: +94.48%
Tyra Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $37.01
Upside: +59.42%
Sagimet Biosciences
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $5.14
Upside: +55.64%
PTC Therapeutics
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $66.75
Upside: +78.28%
MBX Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $66
Current: $29.80
Upside: +121.48%
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $440.83
Upside: +118.68%
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $6.08
Upside: +196.05%
Jan 28, 2026
Initiates: Overweight
Price Target: $231
Current: $144.60
Upside: +59.75%
Jan 28, 2026
Initiates: Overweight
Price Target: $342
Current: $231.03
Upside: +48.04%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $8.48
Upside: +289.15%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $71.03
Upside: +12.63%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $24
Current: $18.87
Upside: +27.19%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $318.91
Upside: +65.25%
Jan 7, 2026
Assumes: Neutral
Price Target: $40 → $34
Current: $53.31
Upside: -36.22%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.62
Upside: +562.98%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $64.78
Upside: -69.13%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $16.66
Upside: -27.97%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.15
Upside: +272.09%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $12.28
Upside: +71.01%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $79.60
Upside: -12.06%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $2.71
Upside: -18.82%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $99.00
Upside: -28.28%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $90.54
Upside: +44.69%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $23.31
Upside: -78.55%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $46.07
Upside: -60.93%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $16.35
Upside: +34.56%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $8.79
Upside: +434.70%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.37
Upside: +11.34%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $32.70
Upside: +309.79%